



**Commercial/Healthcare Exchange PA Criteria**  
*Effective: November 13, 2019*

**Prior Authorization:** Akliief

**Products Affected:** Akliief (trifarotene) 0.005% topical cream

**Medication Description:** Akliief (trifarotene) is indicated for the topical treatment of acne vulgaris in patients nine years of age and older.

**Covered Uses:** Acne Vulgaris

**Exclusion Criteria:** N/A

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried/failed

**Age Restrictions:** 9 years of age and older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:**

- A. Patient has a diagnosis of acne vulgaris; **AND**
- B. Patient has tried at least TWO other formulary alternatives (e.g., Benzoyl peroxide/clindamycin, Benzoyl peroxide, Clindamycin, Clindamycin Phosphate/Benzoyl peroxide, Sodium sulfacetamide, Erythromycin gel, Erythromycin-Benzoyl).

**References:**

1. Akliief [package insert]. Fort Worth, TX; Galderma Laboratories LP; October 2019.
2. Akliief. Lexi-Drugs [database online]. Hudson, OH: Lexicomp Inc; 2014. <http://online.lexi.com>. Accessed October 30, 2019.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/13/2019

Last Res. Date: 11.13.19